BDBM227706 3-{6-[(5-chloropyridin-2- yl)oxy]-7-[(trans-4- methylcyclohexyl)methyl]- 8-[(3r)-3- phenylmorpholin-4-yl]- 7h-purin-2-yl}-1,2,4- oxadiazol-5(4h)-one::US9540377, 25.2

SMILES C[C@H]1CC[C@H](Cn2c(N3CCOC[C@H]3c3ccccc3)nc3nc(-c4noc(=O)[nH]4)nc(Oc4ccc(Cl)cn4)c32)CC1

InChI Key InChIKey=XGFVDWNGXIYNFS-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 227706   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 227706BDBM227706(US9540377, 25.2 | 3-{6-[(5-chloropyridin-2- yl)oxy...)
Affinity DataIC50: 15.4nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent